{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:40:34Z","timestamp":1790404834948,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute kidney injury (AKI) predicts poor prognosis in patients with acute myocardial infarction (MI) and diabetes mellitus (DM) is an independent risk factor of AKI. Recent clinical studies have shown the beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and renal outcomes in patients with DM. We recently reported that canagliflozin normalized susceptibility of diabetic rats to AKI after acute MI via \u03b2-hydroxybutyrate-mediated suppression of NOX expression. Here we examined whether the same renoprotective effect is shared by empagliflozin. Serum creatinine levels were not changed by MI induced by coronary artery occlusion in LETO, non-diabetic control rats, and OLETF, obese type 2 diabetic rats. However, immunohistochemistry revealed that MI increased renal expression of NGAL and KIM-1, early markers of tubular injury, by 3.2-fold and 2.6-fold, respectively, in OLETF. These increases in injury markers were not observed in LETO. Pretreatment with empagliflozin of OLETF for 2 weeks improved hyperglycemia, increased blood \u03b2-hydroxybutyrate level, and suppressed MI-induced expression of NGAL and KIM-1. Empagliflozin suppressed upregulation of NOX2 and NOX4 in the kidney of OLETF. Taken together with the results of our previous study, it was concluded that treatment with the SGLT2 inhibitor protects the diabetic kidney from MI-induced AKI.<\/jats:p>","DOI":"10.1038\/s41598-020-64380-y","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T10:03:17Z","timestamp":1588154597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-1297","authenticated-orcid":false,"given":"Atsushi","family":"Kuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukishige","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihito","family":"Moniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marenao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Tanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-7085","authenticated-orcid":false,"given":"Tetsuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"64380_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/ki.2009.295","volume":"76","author":"A Goldberg","year":"2009","unstructured":"Goldberg, A., Kogan, E., Hammerman, H., Markiewicz, W. & Aronson, D. The impact of transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. Kidney Int. 76, 900\u2013906, https:\/\/doi.org\/10.1038\/ki.2009.295 (2009).","journal-title":"Kidney Int."},{"key":"64380_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1161\/CIRCULATIONAHA.111.039909","volume":"125","author":"CS Fox","year":"2012","unstructured":"Fox, C. S. et al. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. Circulation 125, 497\u2013504, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.039909 (2012).","journal-title":"Circulation"},{"key":"64380_CR3","doi-asserted-by":"publisher","first-page":"H1130","DOI":"10.1152\/ajpheart.00205.2017","volume":"313","author":"K Ohno","year":"2017","unstructured":"Ohno, K. et al. Diabetes increases the susceptibility to acute kidney injury after myocardial infarction through augmented activation of renal Toll-like receptors in rats. Am. J. Physiol. Heart Circ. Physiol 313, H1130\u2013H1142, https:\/\/doi.org\/10.1152\/ajpheart.00205.2017 (2017).","journal-title":"Am. J. Physiol. Heart Circ. Physiol"},{"key":"64380_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/jdi.13009","volume":"10","author":"Y Kimura","year":"2019","unstructured":"Kimura, Y. et al. Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. J. Diabetes Investig. 10, 933\u2013946, https:\/\/doi.org\/10.1111\/jdi.13009 (2019).","journal-title":"J. Diabetes Investig."},{"key":"64380_CR5","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jacc.2010.11.051","volume":"57","author":"M Haase","year":"2011","unstructured":"Haase, M. et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J. Am. Coll. Cardiol. 57, 1752\u20131761, https:\/\/doi.org\/10.1016\/j.jacc.2010.11.051 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"64380_CR6","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.jtcvs.2017.12.056","volume":"155","author":"C Albert","year":"2018","unstructured":"Albert, C. et al. Urinary biomarkers may provide prognostic information for subclinical acute kidney injury after cardiac surgery. J. Thorac. Cardiovasc. Surg. 155, 2441\u20132452 e2413, https:\/\/doi.org\/10.1016\/j.jtcvs.2017.12.056 (2018).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"64380_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner, C. et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. 375, 323\u2013334, https:\/\/doi.org\/10.1056\/NEJMoa1515920 (2016).","journal-title":"N. Engl. J. Med."},{"key":"64380_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 380, 2295\u20132306, https:\/\/doi.org\/10.1056\/NEJMoa1811744 (2019).","journal-title":"N. Engl. J. Med."},{"key":"64380_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 380, 347\u2013357, https:\/\/doi.org\/10.1056\/NEJMoa1812389 (2019).","journal-title":"N. Engl. J. Med."},{"key":"64380_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000498963","volume":"44","author":"C Chu","year":"2019","unstructured":"Chu, C., Lu, Y. P., Yin, L. & Hocher, B. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury. Kidney Blood Press. Res. 44, 149\u2013157, https:\/\/doi.org\/10.1159\/000498963 (2019).","journal-title":"Kidney Blood Press. Res."},{"key":"64380_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1124\/jpet.118.253666","volume":"368","author":"H Oshima","year":"2019","unstructured":"Oshima, H. et al. Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats. J. Pharmacol. Exp. Ther. 368, 524\u2013534, https:\/\/doi.org\/10.1124\/jpet.118.253666 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"64380_CR12","doi-asserted-by":"publisher","first-page":"e13741","DOI":"10.14814\/phy2.13741","volume":"6","author":"M Mizuno","year":"2018","unstructured":"Mizuno, M. et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiol. Rep. 6, e13741, https:\/\/doi.org\/10.14814\/phy2.13741 (2018).","journal-title":"Physiol. Rep."},{"key":"64380_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12933-015-0264-6","volume":"14","author":"H Murase","year":"2015","unstructured":"Murase, H. et al. Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats. Cardiovasc. Diabetol. 14, 103, https:\/\/doi.org\/10.1186\/s12933-015-0264-6 (2015).","journal-title":"Cardiovasc. Diabetol."},{"key":"64380_CR14","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1292\/jvms.61.1219","volume":"61","author":"K Kawano","year":"1999","unstructured":"Kawano, K., Mori, S., Hirashima, T., Man, Z. W. & Natori, T. Examination of the pathogenesis of diabetic nephropathy in OLETF rats. J. Vet. Med. Sci. 61, 1219\u20131228, https:\/\/doi.org\/10.1292\/jvms.61.1219 (1999).","journal-title":"J. Vet. Med. Sci."},{"key":"64380_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B. & List, J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 15, 853\u2013862, https:\/\/doi.org\/10.1111\/dom.12127 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"64380_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi, S. E. et al. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 41, 356\u2013363, https:\/\/doi.org\/10.2337\/dc17-1096 (2018).","journal-title":"Diabetes Care"},{"key":"64380_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05667-5","volume":"7","author":"S Muratsubaki","year":"2017","unstructured":"Muratsubaki, S. et al. Suppressed autophagic response underlies augmentation of renal ischemia\/reperfusion injury by type 2 diabetes. Sci. Rep. 7, 5311, https:\/\/doi.org\/10.1038\/s41598-017-05667-5 (2017).","journal-title":"Sci. Rep."},{"key":"64380_CR18","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1111\/ajt.13368","volume":"15","author":"AS Karim","year":"2015","unstructured":"Karim, A. S. et al. Nox2 is a mediator of ischemia reperfusion injury. Am. J. Transpl. 15, 2888\u20132899, https:\/\/doi.org\/10.1111\/ajt.13368 (2015).","journal-title":"Am. J. Transpl."},{"key":"64380_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.freeradbiomed.2018.06.042","volume":"124","author":"Q Yang","year":"2018","unstructured":"Yang, Q. et al. Nox4 in renal diseases: An update. Free. Radic. Biol. Med. 124, 466\u2013472, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.06.042 (2018).","journal-title":"Free. Radic. Biol. Med."},{"key":"64380_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney, D. Z. et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129, 587\u2013597, https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005081 (2014).","journal-title":"Circulation"},{"key":"64380_CR21","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"V Vallon","year":"2014","unstructured":"Vallon, V. et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am. J. Physiol. Ren. Physiol 306, F194\u2013204, https:\/\/doi.org\/10.1152\/ajprenal.00520.2013 (2014).","journal-title":"Am. J. Physiol. Ren. Physiol"},{"key":"64380_CR22","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1089\/neu.2017.5192","volume":"34","author":"G Kong","year":"2017","unstructured":"Kong, G. et al. The Ketone Metabolite beta-Hydroxybutyrate Attenuates Oxidative Stress in Spinal Cord Injury by Suppression of Class I Histone Deacetylases. J. Neurotrauma 34, 2645\u20132655, https:\/\/doi.org\/10.1089\/neu.2017.5192 (2017).","journal-title":"J. Neurotrauma"},{"key":"64380_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/dom.12322","volume":"16","author":"S Sha","year":"2014","unstructured":"Sha, S. et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 16, 1087\u20131095, https:\/\/doi.org\/10.1111\/dom.12322 (2014).","journal-title":"Diabetes Obes. Metab."},{"key":"64380_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12090","volume":"15","author":"JF Yale","year":"2013","unstructured":"Yale, J. F. et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. 15, 463\u2013473, https:\/\/doi.org\/10.1111\/dom.12090 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"64380_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/dia.2013.0167","volume":"16","author":"S Mudaliar","year":"2014","unstructured":"Mudaliar, S. et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol. Ther. 16, 137\u2013144, https:\/\/doi.org\/10.1089\/dia.2013.0167 (2014).","journal-title":"Diabetes Technol. Ther."},{"key":"64380_CR26","doi-asserted-by":"publisher","first-page":"53028","DOI":"10.18632\/oncotarget.18081","volume":"8","author":"CT Chao","year":"2017","unstructured":"Chao, C. T., Wang, J., Wu, H. Y., Chien, K. L. & Hung, K. Y. Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes. Oncotarget 8, 53028\u201353040, https:\/\/doi.org\/10.18632\/oncotarget.18081 (2017).","journal-title":"Oncotarget"},{"key":"64380_CR27","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/bph.13822","volume":"174","author":"C Reichetzeder","year":"2017","unstructured":"Reichetzeder, C. et al. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury. Br. J. Pharmacol. 174, 2273\u20132286, https:\/\/doi.org\/10.1111\/bph.13822 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"64380_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2369-13-25","volume":"13","author":"M Han","year":"2012","unstructured":"Han, M., Li, Y., Liu, M., Li, Y. & Cong, B. Renal neutrophil gelatinase associated lipocalin expression in lipopolysaccharide-induced acute kidney injury in the rat. BMC Nephrol. 13, 25, https:\/\/doi.org\/10.1186\/1471-2369-13-25 (2012).","journal-title":"BMC Nephrol."},{"key":"64380_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/path.2175","volume":"212","author":"MM van Timmeren","year":"2007","unstructured":"van Timmeren, M. M. et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J. Pathol. 212, 209\u2013217, https:\/\/doi.org\/10.1002\/path.2175 (2007).","journal-title":"J. Pathol."},{"key":"64380_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/DMSO.S58786","volume":"7","author":"SP Vickers","year":"2014","unstructured":"Vickers, S. P. et al. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab. Syndr. Obes. 7, 265\u2013275, https:\/\/doi.org\/10.2147\/DMSO.S58786 (2014).","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64380-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64380-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64380-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T10:04:51Z","timestamp":1670321091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64380-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64380"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64380-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"6 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was partly supported by a grant from Boehringer Ingelheim Pharmaceuticals and by a donation by Mr. Yasuyuki Takeda. They did not play any role in the collection, analysis and interpretation of data or the writing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7238"}}